Schall, Brown & Schwartz LLP Files Class Action Against Beta Bionics

LOS ANGELES, Sept. 8, 2026 /CourierPR/ -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, has filed a federal securities class action lawsuit against Beta Bionics, Inc., the maker of the iLet bionic pancreas insulin pump. The lawsuit, filed on behalf of investors who purchased Beta Bionics securities between July 30, 2025, and February 24, 2026, alleges that the company and certain of its top executives violated the Securities Exchange Act of 1934.

According to the complaint, Beta Bionics made false and misleading statements to the market about the safety, efficacy, and commercial success of its iLet insulin pump. During the class period, the company repeatedly assured investors that the FDA's Form 483, which followed an inspection of the company's manufacturing facility, concerned only the criteria for deciding which customer complaints were reportable and reflected no underlying problems with the device. The complaint alleges that the FDA's findings actually reached the company's quality management system, its investigation and correction of known device malfunctions, and the risk analysis for the device itself. The events the company had failed to report included serious injuries.

Following the emergence of further information, it became clear that the unreported events were far more serious than the company had initially represented, and the FDA's objections were not confined to a difference in regulatory interpretation. As the truth emerged, the price of Beta Bionics common stock declined, leading to significant losses for investors.

The complaint highlights that the company's assurances to investors were misleading. Despite repeated claims that the FDA's findings were not indicative of any underlying issues, the company had been withholding serious information from the public and regulatory bodies. This, according to the lawsuit, constitutes a violation of securities laws and corporate responsibilities.

Beta Bionics investors who purchased shares of BBNX between July 30, 2025, and February 24, 2026, are encouraged to contact Schall, Brown & Schwartz LLP to discuss their potential eligibility for compensation. The firm, known for its expertise in securities class action lawsuits and shareholder rights litigation, has a track record of recovering over a billion dollars for investors.

Schall, Brown & Schwartz LLP invites potential lead plaintiffs to contact the firm at 310-301-3335 or through their website at www.schallfirm.com to learn more about their rights and how they can participate in the lawsuit. The deadline for investors to seek appointment as lead plaintiff is November 3, 2026.